---
title: "CRIS: Emavusertib shows superior efficacy and safety in NHL, CLL, and AML, advancing in registrational trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293485845.md"
description: "Emavusertib, a dual IRAK4-FLT3 inhibitor, demonstrated strong preclinical and clinical activity in NHL, CLL, and AML, with deeper and more durable responses than current standards, especially in PCNSL and mFLT3 AML. Safety profile is favorable, and registrational studies are ongoing.Original document: Curis, Inc. [CRIS] Slides Release — Jul. 22 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-22T14:05:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293485845.md)
  - [en](https://longbridge.com/en/news/293485845.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293485845.md)
generator: "portal-rs"
---

# CRIS: Emavusertib shows superior efficacy and safety in NHL, CLL, and AML, advancing in registrational trials

Emavusertib, a dual IRAK4-FLT3 inhibitor, demonstrated strong preclinical and clinical activity in NHL, CLL, and AML, with deeper and more durable responses than current standards, especially in PCNSL and mFLT3 AML. Safety profile is favorable, and registrational studies are ongoing.

Original document: Curis, Inc. \[CRIS\] Slides Release — Jul. 22 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [CRIS.US](https://longbridge.com/en/quote/CRIS.US.md)

## Related News & Research

- [CRIS: Emavusertib shows strong response rates in PCNSL and advances in CLL, pending further funding](https://longbridge.com/en/news/293464781.md)
- [Curis notifies press release availability on positive emavusertib update](https://longbridge.com/en/news/293462544.md)
- [Moleculin highlights interim data from pivotal MIRACLE Phase 2/3 Annamycin trial in relapsed/refractory AML](https://longbridge.com/en/news/297191000.md)
- [Corvus publishes final Phase 1/1b soquelitinib data in Blood supporting Phase 3 relapsed/refractory PTCL trial](https://longbridge.com/en/news/297177476.md)
- [Can Komzifti's Early Adoption Support Kura Oncology's Next Phase Of Growth?](https://longbridge.com/en/news/296928079.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**